EC Number   |
Substrates |
Organism |
Products |
Reversibility |
|---|
   6.3.2.47 | ATP + 3-((((2R,3R)-3-carboxyoxiran-2-yl)carbonyl)amino)-L-alanine + L-valine |
i.e. N-beta-epoxysuccinamoyl-2,3-diaminopropionate. DdaF can catalyze the ligation of both Nbeta-trans-epoxysuccinamoyl-diaminopropionate diastereomers to Val to produce the Nbeta-trans-epoxysuccinamoyl-diaminopropionate-L-valine dipeptide antibiotics. DdaF uses (R,R)-Nbeta-trans-epoxysuccinamoyl-diaminopropionate as a saturable substrate, whereas saturation is not achieved with (S,S)-Nbeta-trans-epoxysuccinamoyl-diaminopropionate at concentrations up to 590 microM |
Pantoea agglomerans |
ADP + phosphate + 3-((((2R,3R)-3-carboxyoxiran-2-yl)carbonyl)amino)-L-alanyl-L-valine |
product is a natural antibiotic |
? |
| 6.3.2.47 | ATP + 3-[[(2E)-4-amino-4-oxobut-2-enoyl]amino]-L-alanine + L-isoleucine |
- |
Pantoea agglomerans |
ADP + phosphate + 3-(((2E)-4-amino-4-oxobut-2-enoyl)amino)-L-alanyl-L-isoleucine |
- |
? |
| 6.3.2.47 | ATP + 3-[[(2E)-4-amino-4-oxobut-2-enoyl]amino]-L-alanine + L-leucine |
- |
Pantoea agglomerans |
ADP + phosphate + 3-(((2E)-4-amino-4-oxobut-2-enoyl)amino)-L-alanyl-L-leucine |
- |
? |
| 6.3.2.47 | ATP + 3-[[(2E)-4-amino-4-oxobut-2-enoyl]amino]-L-alanine + L-valine |
- |
Pantoea agglomerans |
ADP + phosphate + 3-(((2E)-4-amino-4-oxobut-2-enoyl)amino)-L-alanyl-L-valine |
- |
? |
| 6.3.2.47 | ATP + 3-[[(2E)-4-amino-4-oxobut-2-enoyl]amino]-L-alanine + L-valine |
i.e. Nbeta-fumaramoyl-diaminopropionate |
Pantoea agglomerans |
ADP + phosphate + 3-[[(2E)-4-amino-4-oxobut-2-enoyl]amino]-L-alanyl-L-valine |
- |
? |
| 6.3.2.47 | more |
DdaF will not accept Nbeta-fumaroyl-diaminopropionate or Nalpha-fumaramoyl-diaminopropionate. The enzyme requires the fumaroyl moiety to be first converted to the fumaramoyl half amide in Nbeta-fumaramoyl-diaminopropionate |
Pantoea agglomerans |
? |
- |
? |
